[go: up one dir, main page]

TR201720672A2 - CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS OF IVABRADINE - Google Patents

CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS OF IVABRADINE Download PDF

Info

Publication number
TR201720672A2
TR201720672A2 TR2017/20672A TR201720672A TR201720672A2 TR 201720672 A2 TR201720672 A2 TR 201720672A2 TR 2017/20672 A TR2017/20672 A TR 2017/20672A TR 201720672 A TR201720672 A TR 201720672A TR 201720672 A2 TR201720672 A2 TR 201720672A2
Authority
TR
Turkey
Prior art keywords
controlled release
ivabradine
pharmaceutical compositions
release pharmaceutical
polymorph
Prior art date
Application number
TR2017/20672A
Other languages
Turkish (tr)
Inventor
Güner Di̇cle
Palantöken Arzu
Türkyilmaz Ali̇
Original Assignee
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi filed Critical Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
Priority to TR2017/20672A priority Critical patent/TR201720672A2/en
Priority to PCT/TR2018/050818 priority patent/WO2019209208A2/en
Publication of TR201720672A2 publication Critical patent/TR201720672A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Mevcut buluş, ivabradin veya farmasötik olarak kabul edilebilir bir tuzunu, solvatını veya polimorfunu ve en az bir kontrollü salım ajan içeren kontrollü salımlı farmasötik kompozisyonlarla ilgilidir.The present invention relates to controlled release pharmaceutical compositions comprising ivabradine or a pharmaceutically acceptable salt, solvate or polymorph and at least one controlled release agent.

TR2017/20672A 2017-12-18 2017-12-18 CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS OF IVABRADINE TR201720672A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
TR2017/20672A TR201720672A2 (en) 2017-12-18 2017-12-18 CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS OF IVABRADINE
PCT/TR2018/050818 WO2019209208A2 (en) 2017-12-18 2018-12-17 Controlled-release pharmaceutical compositions of ivabradine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TR2017/20672A TR201720672A2 (en) 2017-12-18 2017-12-18 CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS OF IVABRADINE

Publications (1)

Publication Number Publication Date
TR201720672A2 true TR201720672A2 (en) 2019-07-22

Family

ID=67900851

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2017/20672A TR201720672A2 (en) 2017-12-18 2017-12-18 CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS OF IVABRADINE

Country Status (2)

Country Link
TR (1) TR201720672A2 (en)
WO (1) WO2019209208A2 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010128525A2 (en) * 2009-05-04 2010-11-11 Dinesh Shantilal Patel A formulation of ivabradine for treating the cardiovascular disease
PT2579858E (en) * 2010-06-14 2014-07-18 Ratiopharm Gmbh Ivabradine-containing pharmaceutical composition
CN102908327B (en) * 2011-08-05 2015-03-11 江苏恒瑞医药股份有限公司 Sustained release preparation for ivabradine or medicinal salt thereof

Also Published As

Publication number Publication date
WO2019209208A2 (en) 2019-10-31
WO2019209208A3 (en) 2020-01-16

Similar Documents

Publication Publication Date Title
MY197700A (en) Compounds useful for inhibiting cdk7
MX2018001990A (en) Compositions comprising a pi3k inhibitor and an hdac inhibitor.
PH12019501639A1 (en) Jaki selective inhibitors
PH12018500047B1 (en) Notch pathway signaling inhibitor compounds
ZA201708234B (en) Delivery systems for controlled drug release
MX2017014994A (en) ORAL SOLID FORMULATION CONTAINING IRINOTECHAN AND METHOD OF PREPARATION OF THE SAME.
MX2016014939A (en) CARBOXAMIDE DERIVATIVES
EP3438303A4 (en) DEGRADABLE MG ALLOY
MX2016013431A (en) Pharmaceutical compositions comprising antibacterial agents.
MX2020005483A (en) Ildr2 antagonists and combinations thereof.
JO3456B1 (en) ferrotioxetine pyroglutamate
MA49837A (en) PHARMACEUTICAL COMPOSITIONS
MY182634A (en) Pharmaceutical containing sodium-dependent phosphate transporter inhibitor
EA201990313A1 (en) DERIVATIVE TRIAZOLOPYRAZINONE USED AS A HUMAN PDE1 INHIBITOR
MX376741B (en) PHARMACEUTICAL COMPOSITION OF SULFONAMIDE
WO2016006975A3 (en) Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof
WO2016006974A3 (en) Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof
MX2019008338A (en) Pharmaceutical composition containing sulglycotide or pharmaceutically acceptable salt thereof for preventing or treating dry eye.
MY180727A (en) Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzeimer?s disease
DK3638211T3 (en) DELAYED SUSTAINED RELEASE PHARMACEUTICAL COMPOSITIONS
TR201720672A2 (en) CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS OF IVABRADINE
TR201715231A2 (en) The pharmaceutical combination comprising dapoxetine and phosphodiesterase type-5
MX2016013428A (en) Pharmaceutical compositions comprising antibacterial agents.
MA49625A (en) PHARMACEUTICAL COMPOSITIONS
EA201791596A1 (en) PYRAZOL COMPOUNDS